A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
DDDr. Dereck Mush, MD, MBA
Sep 3
Scholar Rock
A biopharmaceutical company developing medicines that target growth factors in their local tissue environments.
What they do
Scholar Rock applies its selective myostatin biology platform to neuromuscular diseases, including apitegromab for spinal muscular atrophy.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Neuromuscular and rare diseases
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Cambridge, USA
- Region
- North America
- Founded
- 2012
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
AI Just Helped Solve 18 Medical Mysteries Doctors Couldn't Crack
DDDr. Dereck Mush, MD, MBA
Jun 25
The senolytic drug pipeline is narrowing toward a smaller set of credible candidates
DDDr. Dereck Mush, MD, MBA
Apr 14